Clinical Trial Update: Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating AVE5026 versus placebo for extended prevention of venous thromboembolism in patients following hip fracture surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• AVE5026

Snippet

Sponsor: Sanofi | Conditions: Venous Thromboembolism | Phase 3 | Status: COMPLETED